IBSRELA (Tenapanor) for IBS-C - IBSRELA is a first-in-class therapy for Irritable Bowel Syndrome with Constipation (IBS-C) in adults, indicated at 50 mg BID[8, 28] - In clinical trials, diarrhea was a common adverse reaction, occurring in 16% of IBSRELA-treated patients versus 4% in the placebo group[7, 32] - A Spherix survey reported that 60% of surveyed GIs have adopted IBSRELA[13] - IBSRELA recorded $15.6 million in net sales since launch in March 2022 (as of Dec 31, 2022)[19, 39] - The U S IBS-C market has 5 2 million prescriptions for indicated products in 2022[22, 34] and $3 1 billion in sales[24] XPHOZAH (Tenapanor) for Hyperphosphatemia - XPHOZAH is an investigational, first-in-class phosphate absorption inhibitor for hyperphosphatemia treatment, pending FDA review[42] - In clinical trials, diarrhea (47%) was the most common adverse reaction reported in XPHOZAH-treated patients[54] - A Spherix survey reported that 72% of nephrologists reported a high interest in XPHOZAH[59] - Approximately 80% of over 550,000 U S patients with CKD on dialysis require Rx treatment for hyperphosphatemia[42, 45] Corporate Strategy and Financials - Ardelyx is focused on developing and commercializing therapies for unmet needs in established therapeutic areas[15, 74] - Ardelyx had $123.9 million in cash and investments as of December 31, 2022[69]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-K ____________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36485 ___ ...

Ardelyx, Inc. (NASDAQ:ARDX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Kimia Keshtbod - Investor Relations Justin Renz - Chief Financial Officer Susan Rodriguez - Chief Commercial Officer Laura Williams - Chief Medical Officer David Rosenbaum - Chief Development Officer Rob Blanks - Chief Regulatory Affairs and Quality Assurance Officer Conference Call Participants Yigal Nochomovitz - Citigroup Laura Chico - Wedbush Securities Joseph Thome - Cowen and Company Matt Kapl ...

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Justin Renz - CFO & Treasurer Michael Raab - President, CEO & Director Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs & Quality Assurance Officer Conference Call Participants Christopher Howerton - Jefferies Matthew Kaplan - Ladenburg Thalmann & Co. John Bohnsack - Cowen and Company Operator Good afternoon, and welcome to the Ardelyx's Second Quarter 2022 Conferenc ...

Ardelyx, Inc. (NASDAQ:ARDX) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Justin Renz - Chief Financial Officer Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs and Quality Assurance Officer Conference Call Participants Chris Howerton - Jeffrey Carly Kenselaar - Citi Joseph Thome - Cowen and Company Sam Brandeis - Wedbush Matthew Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome ...